The Tie-Breaker Benefit: Choosing an SGLT2 Inhibitor Partly for Its Effect on Gout
A single patient qualifies for more than one next-step medication for her diabetes and heart failure. The disagreement is whether her separate, ongoing gout should be allowed to help break the tie.
Carla N., a 58-year-old middle school administrator, started tracking her daily steps on her phone last year after her cardiologist mentioned her heart failure diagnosis "doesn't have to mean sitting still," and has since worked her way up to a slow but steady two miles most evenings, timed deliberately for after dinner so it doesn't compete with the evening phone calls she still fields from parents. She has had type 2 diabetes for nine years, HFrEF with an ejection fraction of 34% diagnosed fourteen months ago, and gout for the past three years, with two flares this year despite reasonably controlled urate on allopurinol. She is already on metformin, a beta-blocker, and an ACE inhibitor, and today's visit is about what comes next — her endocrinologist and cardiologist agree she needs an additional agent, but not yet which one.
Two reasonable next steps sit on the table for different reasons. An SGLT2 inhibitor is guideline- recommended for essentially every patient with her combination of type 2 diabetes and HFrEF, regardless of glycemic control, on the strength of trials like DAPA-HF and EMPEROR-Reduced showing reduced heart-failure hospitalization independent of diabetes status. A mineralocorticoid receptor antagonist is also a reasonable next step for HFrEF specifically. What tips this particular decision, though, is a finding that sits outside either heart-failure trial: newer cohort data from the last two years associate SGLT2 inhibitor use with a meaningfully lower rate of gout flares, plausibly through the drug class's effect on renal urate handling rather than through glycemic control itself. That evidence isn't randomized, and it wasn't the reason either drug earned its heart-failure indication — but Carla is exactly the patient in whom two otherwise-comparable options stop being comparable once her second, unrelated disease is allowed into the room.
Two reasonable next steps, and a third disease in the room
Either drug is defensible on the heart-failure evidence alone — DAPA-HF and EMPEROR-Reduced for the SGLT2 inhibitor, comparable MRA trial data on the other side. Since that leaves us genuinely undecided between them, I think it's fair to let her gout tip the balance. The cohort data linking this drug class to fewer flares, likely through its effect on renal urate handling, is real even if it isn't randomized — and she's had two flares this year on urate that isn't quite at goal.
I'd be careful about how much weight that gets. The heart-failure trials for both drug classes are randomized, controlled, and built specifically to answer the question we're actually asking here. The gout association is cohort-level evidence for a different condition entirely — real, worth knowing about, but not evidence of the same kind, and I wouldn't want it doing the deciding work in a decision this consequential.
I'm not saying ignore it. I'm saying a tie between two trial-proven options shouldn't be broken by evidence that wasn't designed to break ties like this one.
We may not need the gout data to settle this at all. Her A1c is 7.4%, above her own individualized goal, and the SGLT2 inhibitor is the one of the two options that also meaningfully lowers glucose — the MRA doesn't touch glycemic control. That alone is a clean, independent reason to prefer it, without asking anyone to lean on evidence they're not fully comfortable weighting. The gout benefit, if it holds up, is a welcome bonus rather than the deciding argument.
Agreed: empagliflozin started, with allopurinol continued and flagged for possible uptitration at her next urate check. All three voices ultimately converged on the same drug, though not for identical reasons — the glycemic argument carried the final decision more than the gout association did.
Left as an open question, not a disagreement: whether her flare frequency actually falls over the next year in a way attributable to the SGLT2 inhibitor specifically, given that her allopurinol dose may also be adjusted in the same interval. The endocrinologist plans to track it as a genuine real-world data point for her own future practice, not as something this case needed to settle today.